Expires September 25, 2022
Video length: 39 minutes
In this month's "Virtual Lecture," Ann Moyer, M.D., Ph.D., describes how pharmacogenomics and therapeutic drug monitoring tools aid medical providers in selecting drugs and doses to maximize efficacy while minimizing toxicity for mental illnesses, including depression.
Upon completion of this program, participants should be able to:
This program is appropriate for clinicians, pathologists, medical technologists, nurses, pharmacists, and other allied health staff.
The following types of credit are offered for this program:
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 0.5 P.A.C.E.® contact hours.
To obtain credit:
Level of instruction for this program is basic.
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Contact us: email@example.com